<?xml version="1.0" encoding="UTF-8"?>
<p>Holshue et al
 <sup>[
  <xref rid="R28" ref-type="bibr">28</xref>]
 </sup> reported the trial administration of intravenous Remdesivir after the first confirmed patient's deterioration in the United States and found that raloxifene may have a good effect on inhibiting SARS-COV-2. Remdesivir is a novel ribonucleic acid analog under development that is superior to Lopinavir/Ritonavir in combination with interferon-beta in the treatment of MERS-CoV.
 <sup>[
  <xref rid="R11" ref-type="bibr">11</xref>]
 </sup>
</p>
